# KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

> **NCT06026410** · PHASE1 · RECRUITING · sponsor: **Kura Oncology, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Solid Tumors With HRAS Alterations
- Non Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Renal Cell Carcinoma (Kidney Cancer)
- Non Clear Cell Renal Cell Carcinoma (nccRCC)

## Interventions

- **DRUG:** Darlifarnib
- **DRUG:** Cabozantinib
- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT06026410
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026410, "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06026410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*